StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report report published on Sunday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 3.3 %

Shares of Brooklyn ImmunoTherapeutics stock opened at $0.38 on Friday. The stock has a market capitalization of $22.26 million, a price-to-earnings ratio of -0.17 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a twelve month low of $0.17 and a twelve month high of $10.10. The business’s 50 day simple moving average is $0.36 and its 200-day simple moving average is $0.99.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.